Return to News


Neural ID to Exhibit at Safety Pharmacology Society (SPS) Annual Meeting


Chief Scientist Tyson Thomas to Present Latest Research on Scalable Analysis Platform for Multi-Electrode Array Cardiomyocyte Data


September 16, 2013


REDWOOD CITY, CA  --  Neural ID, the leader in waveform analytics solutions for the life sciences industry, today announced the company will be exhibiting at the Safety Pharmacology Society (SPS) Annual Meeting held in Rotterdam, Netherlands on September 16-19, 2013. Dr. Tyson Thomas, Neural ID’s Chief Scientist, will present a scientific poster co-authored with a team from GlaxoSmithKline on research that demonstrated for the first time a scalable analysis platform for multi-electrode array (MEA) cardiomyocyte data.


“Neural ID products offer an exciting advancement in the analysis and management of the overwhelming volumes of drug discovery and development data,” said Tim Carruthers, CEO of Neural ID. “Our enterprise software improved reporting and analysis by five times compared to existing tools.”


Neural ID will be demonstrating their Intelligent Waveform Service (IWS). The proprietary enterprise software automates recognition and analysis of biosignals using a pattern-based methodology with advanced machine learning to accelerate biopharmaceutical research. IWS provides researchers with more complete results at a fraction of the time and cost.


The SPS Annual Meeting is the most focused scientific meeting targeting the role of safety pharmacology in drug development. Presentations cover a spectrum from theory to practical experience and specific case studies. This event is one of the best forums for international "best practice sharing" within the pharmaceutical industry and offers a comprehensive program of continuing education courses to accommodate both newcomers to the field as well as those with experience in advanced courses.



About Neural ID

Neural ID offers the only scalable enterprise solution for waveform analytics. Powered by patented pattern recognition technology, the Intelligent Waveform Service (IWS) provides automated biosignal recognition and analysis to accelerate drug development. Based in Redwood City, California, Neural ID accelerates research, expands capacity and reduces costs to leading organizations worldwide. For additional information, please visit or call 650-394-8800.



"The combination of AI with these new drug discovery platforms will speed the delivery of new drug therapies and revolutionize Life Sciences productivity.”

— Neural Dude






© 2013 Neural ID

Neural ID

Providing enterprise-class waveform analytics
to the Health Sciences industry

Neural ID

Post Office Box 123

San Carlos, CA 94070